Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 40.39
- Piotroski Score 5.00
- Grade Buy
- Symbol (CLDX)
- Company Celldex Therapeutics, Inc.
- Price $32.63
- Changes Percentage (-4%)
- Change -$1.36
- Day Low $32.59
- Day High $34.50
- Year High $53.18
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/31/2024
- Fiscal Year End N/A
- Average Stock Price Target $58.00
- High Stock Price Target $63.00
- Low Stock Price Target $44.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.86
- Trailing P/E Ratio -12.34
- Forward P/E Ratio -12.34
- P/E Growth -12.34
- Net Income $-141,429,000
Income Statement
Quarterly
Annual
Latest News of CLDX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Celldex Therapeutics, Inc. (CLDX): Short Seller Sentiment is Bearish on This Cancer Stock
Cancer stocks are a significant sector in life sciences, with a growing burden due to various factors. Companies are developing innovative therapies, driving the market's growth to over $518 billion b...
By Yahoo! Finance | 2 weeks ago -
Companies Like Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Invest In Growth
Despite losing money, shareholders can still profit by investing in a good business at the right price. Analyzing Celldex Therapeutics' cash burn rate reveals it has a 6.8-year cash runway, with poten...
By Yahoo! Finance | 2 months ago
